PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12188416::ACT019237

tyroserleutide

Evidence text

Paper-level observation

in the presence of 4.0 μM 5F–C12, the anticancer activity of YSL was remarkably potentiated, lowering the IC50 to 0.27 mM, corresponding to an improvement of 16.1-fold.
textConfidence: medium

Assay observation

Activity
Anticancer
Subtype
Not reported by source
Measure
other
Comparator
=
Raw observation
0.27 mM
Normalized measurement
=0.27 other
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
MCF-7
Assay method
Not reported by source
Sequence
YSL
Standardization
ready simple

Source publication

Artificial Tyroserleutide Transporters for Synergistic Cancer Therapy.

JACS Au · 2025

DOI 10.1021/jacsau.5c00204 PMC12188416
Parent mention Integrated peptide

Related peptide identities

PEPDIA-PLP-004213PEPDIA-INT-025613

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.